Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
AccuStem Sciences, Inc. is a clinical-stage diagnostics company developing proprietary genomic tests to improve cancer patient outcomes. Its key products include the MSC test for lung nodule malignancy risk and StemPrintER, a multi-gene assay predicting breast cancer recurrence risk. Targeting oncology care providers and patients, AccuStem leverages validated molecular diagnostics to support personalized treatment decisions, focusing initially on the U.S. market with plans for broader tumor applications.
This description was generated via AI from an annual report. Updated about 1 year ago.